Trial Profile

A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naporafenib (Primary) ; Ribociclib (Primary) ; Rineterkib (Primary) ; Trametinib (Primary)
Indications Malignant melanoma; Skin cancer
Focus Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

21 Oct 2025 Planned End Date changed from 30 Oct 2025 to 27 Mar 2026.
21 Oct 2025 Planned primary completion date changed from 29 Oct 2025 to 27 Mar 2026.
31 Jul 2025 Planned End Date changed from 30 Jul 2025 to 30 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com